Relay Therapeutics, Inc.
RLAY- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001812364
In the last 90 days, Relay Therapeutics, Inc. insiders filed 0 open-market purchases and 14 sales; 259 institutions reported holding it in 13F filings for Q2 2026, worth $4.58B in total; Duquesne Family Office is the only superinvestor holding it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $121.7M in total
- 14
- 13F holdersQ2 2026, +20 vs. previous quarter
- 259
- 13F valueReported value at the end of Q2 2026
- $4.58B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding RLAY, Q2 2026
1 superinvestor reports holding Relay Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Duquesne Family Office
Stanley Druckenmiller
0.1%
Relay Therapeutics, Inc.'s share of the portfolio
- Shares
- 349,000
- Value
- $6.53M
Latest insider trades
Open-market purchases and sales by Relay Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 9, 2026 (view filing)4:17 PM ET | Sep 8 | 1 day | Bergstrom Donald APresident, R&D | SSale | −8.53K | $18.97 | −$161.8K | −2.1%399.1K after | 10b5-1 |
| Sep 9, 2026 (view filing)4:15 PM ET | Sep 8 | 1 day | Catinazzo ThomasChief Financial Officer | SSale | −17.7K | $18.94 | −$335.6K | −12.6%122.9K after | 10b5-1 |
| Sep 9, 2026 (view filing)4:12 PM ET | Sep 8 | 1 day | Patel SanjivPresident and CEO | SSale | −48.2K | $18.94 | −$912.9K | −8.5%519.5K after | 10b5-1 |
| Aug 28, 2026 (view filing)4:43 PM ET | Aug 26 | 2 days | Rahmer PeterSee remarks | SSale | −4.51K | $20.03 | −$90.3K | −2.0%223.7K after | 10b5-1 |
| Aug 28, 2026 (view filing)9:01 AM ET | Aug 25 | 3 daysLate | SB Investment Advisers (UK) Ltd and 2 others10% Owner | SSale | −6.00M | $19.40 | −$116.4M | −21.5%21.9M after | |
| Aug 18, 2026 (view filing)4:17 PM ET | Aug 17 | 1 day | Patel SanjivPresident and CEO | SSale | −48.2K | $20.33 | −$979.9K | −7.8%567.7K after | 10b5-1 |
| Aug 18, 2026 (view filing)4:16 PM ET | Aug 14 | 4 days | Catinazzo ThomasChief Financial Officer | SSale | −17.7K | $19.74 | −$349.7K | −11.2%140.6K after | 10b5-1 |
| Jul 30, 2026 (view filing)4:13 PM ET | Jul 28 | 2 days | Catinazzo ThomasChief Financial Officer | SSale | −1.46K | $18.61 | −$27.2K | −0.9%158.3K after | |
| Jul 30, 2026 (view filing)4:13 PM ET | Jul 28 | 2 days | Rahmer PeterSee remarks | SSale | −748 | $18.61 | −$13.9K | −0.3%228.2K after | |
| Jul 30, 2026 (view filing)4:12 PM ET | Jul 28 | 2 days | Bergstrom Donald APresident, R&D | SSale | −2.24K | $18.61 | −$41.6K | −0.5%407.7K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Relay Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| SB Investment Advisers (UK) Ltd | 27,904,963 | $522.1M | 6.81% | 00.0% | Unchanged |
| FMR LLC | 20,110,113 | $376.3M | 0.02% | +16,414,682+444.2% | Added |
| Casdin Capital, LLC | 16,035,240 | $300.0M | 15.02% | +1,616,666+11.2% | Added |
| BlackRock, Inc. | 15,288,202 | $286.0M | 0.00% | +2,312,903+17.8% | Added |
| Perceptive Advisors LLC | 14,106,187 | $263.9M | 4.10% | +4,355,046+44.7% | Added |
| Commodore Capital LP | 12,000,000 | $224.5M | 13.37% | −5,000,000−29.4% | Reduced |
| State Street Corp | 10,125,381 | $189.5M | 0.01% | +3,891,836+62.4% | Added |
| Vanguard Capital Management LLC | 8,964,423 | $167.7M | 0.00% | +1,576,958+21.3% | Added |
| Price T Rowe Associates Inc | 7,708,507 | $144.2M | 0.01% | +5,783,569+300.5% | Added |
| Nextech Invest, Ltd. | 6,776,506 | $126.8M | 6.02% | +1,250,000+22.6% | Added |